Cenobamate Dosage
Medically reviewed by drugclasses.com. Last updated on Jul 12, 2024.
Applies to the following strengths: 25 mg; 50 mg; 100 mg; 150 mg-100 mg (250 mg daily-dose); 200 mg-150 mg (350 mg daily-dose); 150 mg; 200 mg; 12.5 mg-25 mg; 50 mg-100 mg; 150 mg-200 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Seizures
Initial dose: 12.5 mg orally once a day for weeks 1 and 2
Titration: 25 mg orally once a day for weeks 3 and 4; 50 mg orally once a day for weeks 5 and 6; 100 mg orally once a day for weeks 7 and 8; 150 mg orally once a day for weeks 9 and 10
Maintenance Dose (starting at week 11): 200 mg orally once a day
Maximum Dose: 400 mg orally once a day
Comments:
- This drug may be used as monotherapy or as adjunctive therapy.
- Dosage and titration should not be exceeded because of the potential for serious adverse reactions.
- Titration to the maximum dose should be accomplished in increments of 50 mg/day every 2 weeks; the decision to increase the dose above the maintenance dose should be based on clinical response and tolerability.
Use: For the treatment of partial-onset seizures.
Renal Dose Adjustments
Mild to severe renal impairment: Use caution; dose reduction may be considered
ESRD undergoing dialysis: Not recommended
Liver Dose Adjustments
Mild to moderate hepatic impairment (Child-Pugh, Class A or B): Maximum dose: 200 mg/day; although additional dosage reduction may be needed
Severe hepatic impairment: Use is not recommended
Dose Adjustments
Geriatrics: Dose selection should be cautious, usually starting at the low end of the dosing range
Discontinuation of Therapy:
- Discontinue gradually over a period of at least 2 weeks, unless safety concerns require abrupt withdrawal
Precautions
CONTRAINDICATIONS:
- Hypersensitivity to this drug or any of the inactive ingredients
- Familial Short QT syndrome
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
US Controlled Substance: V
Dialysis
Not recommended
Other Comments
Administration advice:
- Take orally once a day; may take any time of day with or without food
- Swallow tablets whole with liquid; do not crush or chew
Monitoring:
- Monitor for changes in mood or behavior including emergence or worsening of depression, suicidal thoughts, or thoughts of self-harm.
- Monitor for somnolence and fatigue
Patient advice:
- Patients should be instructed to read the US FDA-approved patient labeling (Medication Guide).
- Patients should be instructed to avoid stopping this drug abruptly unless instructed to do so by their healthcare provider.
- Patients should be instructed to report a fever or rash associated with signs of other organ system involvement (e.g., lymphadenopathy, hepatic dysfunction); this drug should be discontinued immediately if a serious hypersensitivity reaction is suspected.
- Patients should be instructed to report prolonged heart palpitations or loss of consciousness.
- Patients should be instructed to report any changes in mood or behavior including emergence or worsening of depression, suicidal thoughts, or thoughts of self-harm.
- Patients should understand that this drug may cause somnolence, fatigue, dizziness, and gait disturbances as well as blurred vision or diplopia; patients should be instructed to avoid hazardous tasks until they know how this drug affects them.
- Women who are pregnant or intending to become pregnant should consult with their healthcare provider; women of reproductive potential should understand that this drug may decrease the efficacy of oral contraceptives and they should use additional or alternative non-hormonal birth control.
Frequently asked questions
More about cenobamate
- Check interactions
- Compare alternatives
- Reviews (30)
- Side effects
- During pregnancy
- Drug class: carbamate anticonvulsants
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.